Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on advanced wound care and surgical biologics that completed its public debut in December 2018 through a merger with Avista Healthcare Public Acquisition Corp, a SPAC sponsored by Avista Capital Partners. The deal brought Organogenesis into the public markets within the healthcare and life sciences sector, where it develops and commercializes products designed to support wound healing and tissue regeneration. The company remains publicly traded on Nasdaq and most recently filed a Form 10-Q with the SEC on November 6, 2025. Sign up on SpacDesk for full filings history, sponsor profiles, and deal analytics on ORGO and hundreds of other SPAC-origin companies.